Joshua A. David

Joshua A. David

Auto-generated profile, based on publicly available information

Joshua A. David

Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Cell
Verified
Journal Article
Closed access
AFAndrew I. Flyak
Andrew I. Flyak
XSXiaoli Shen
Xiaoli Shen
CMCharles D. Murin
Charles D. Murin
HTHannah L. Turner
Hannah L. Turner
JDJoshua A. David
Joshua A. David
JCJames E. Crowe
James E. Crowe

25 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RSRanjan K. Singh
Ranjan K. Singh
ASAhmed Soliman
Ahmed Soliman
GGGiambattista Guaitoli
Giambattista Guaitoli
ESEliza Störmer
Eliza Störmer
FZFelix von Zweydorf
Felix von Zweydorf
WVWim Versées
Wim Versées
Significance: Parkinson’s disease (PD) is the second-most common neurodegenerative disorder. Mutations leading to overactivation of LRRK2 are a leading cause of familial PD, and this protein is therefore considered as an appealing target for drug design. Here, we describe the discovery and characterization of a diverse set of LRRK2-targeting nanobodies. A subset of these nanobodies inhibit LRRK2 via a mechanism that differs from the commonly used LRRK2 kinase inhibitors. Importantly, some of these nanobodies selectively inhibit certain LRRK2 activities (Rab phosphorylation) while leaving other activities (autophosphorylation) unaffected. We anticipate that these nanobodies will find multiple applications as research tools and will open up opportunities for the development of new PD diagnostics and therapeutics in parallel to other currently pursued strategies.